Skip to main content

Orgenesis Inc. (ORGS)

NASDAQ: ORGS · Delayed Price · USD
5.08 0.14 (2.83%)
Sep 22, 2021 4:00 PM EDT - Market closed
Market Cap121.21M
Revenue (ttm)23.96M
Net Income (ttm)56.92M
Shares Out24.37M
EPS (ttm)-2.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,316
Open4.94
Previous Close4.94
Day's Range4.86 - 5.08
52-Week Range4.14 - 8.30
Beta1.21
Analystsn/a
Price Target9.00 (+77.2%)
Est. Earnings DateNov 4, 2021

About ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at t...

IndustryBiotechnology
Founded2008
CEOVered Caplan
Employees111
Stock ExchangeNASDAQ
Ticker SymbolORGS
Full Company Profile

Financial Performance

Financial Statements

News

Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis' cell and gene therapy platform

4 weeks ago - GlobeNewsWire

Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

GERMANTOWN, MD / ACCESSWIRE / August 12, 2021 / Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be pr...

1 month ago - Accesswire

Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

1 month ago - GlobeNewsWire

Orgenesis announces use of the Tissue Genesis Icellator® in a Hospital for Special Surgery clinical study for rotator...

Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery Investigator-initiated, rand...

3 months ago - GlobeNewsWire

Orgenesis to Present at the Summer Solstice Conference - Best Ideas from the Buy-Side on June 2nd

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

3 months ago - GlobeNewsWire

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its journe...

4 months ago - Proactive Investors

Orgenesis First Quarter 2021 Revenue Increases 400% to $9.4 Million Reflecting Initial Success of POCare Platform

Achieves operating profit for the first quarter of 2021

4 months ago - GlobeNewsWire

Wall Street mixed at midday despite better than expected jobs data

12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.

Other symbols:ARECMBIIMRNAPESIPFE
4 months ago - Proactive Investors

Orgenesis reaches milestone with US FDA approval of Tissue Genesis Icellator2 pilot trial

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) is poised to carry out the first-in-human trial of its Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome (ARDS) caused by the coronavirus (COVI...

4 months ago - Proactive Investors

Orgenesis Schedules First Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

4 months ago - GlobeNewsWire

Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital in Rome, Italy to establish a point-of-care cell therapy centre there.  Work will focus on suppo...

5 months ago - Proactive Investors

Orgenesis to collaboration with Bambino Gesù Children's Hospital in Rome on new therapy centre

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital - the first such hospital in Italy - to establish a point-of-care cell therapy centre there.  Wo...

5 months ago - Proactive Investors

Orgenesis Enters into Collaboration Agreement with the Bambino Gesù Children's Hospital in Rome to Establish Point of...

GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

5 months ago - GlobeNewsWire

Orgenesis collaborates with MIDA Biotech to establish point-of-care centers at hospitals and other medical institutio...

Orgenesis Inc (NASDAQ:ORGS) announced Thursday that it is collaborating with MIDA Biotech BV to establish point-of-care centers at hospitals and other medical institutions across western Europe. Orgenes...

6 months ago - Proactive Investors

Orgenesis collaboration with Madrid hospital to develop solid tumor treatment Celyvir enters second phase

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Thursday that it has entered the second phase of its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, focused on the hospit...

6 months ago - Proactive Investors

Orgenesis leads the charge at an exciting time for cell and gene therapy

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platfor...

6 months ago - Proactive Investors

Orgenesis expecting revenue to more than double in 2021 as it updates on growth strategy

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, told investors it expects revenue to more than double in 2021, based on its existing contracts alone.  In a sta...

6 months ago - Proactive Investors

Dow adds 600 points to intraday record, tech struggles continue to drag Nasdaq

12:48pm: Dow, Nasdaq headed in opposite directions The Dow was up 605 points, 1.9%, at 32,101 at midday, and the S&P 500 picked up 36 points, almost 1%, to 3,878 points. The Nasdaq, meanwhile, fell 57 p...

Other symbols:ALPPCYDYDISKULR
6 months ago - Proactive Investors

Orgenesis teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing...

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospital in South Korea and Cure Therapeutics Inc to utilize Orgenesis Mobile Proces...

6 months ago - Proactive Investors

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of ...

GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

6 months ago - GlobeNewsWire

Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call

GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

6 months ago - GlobeNewsWire

Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile

Orgenesis is a $151m market cap biotech focused on cell and gene therapy technologies. It has a technology, therapeutics, and point of care platform that enables its CGT partners to develop products in ...

7 months ago - Seeking Alpha

Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform

Reports rapid advancement of therapeutic pipeline

10 months ago - GlobeNewsWire

Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders

GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

10 months ago - GlobeNewsWire